Tapping Into the Therapeutic Expertise of High-Volume Cancer Centers
Researchers examine how patient outcomes could be affected if patients were to receive systemic drug treatment at dedicated cancer centers versus at community health systems.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
MGUS: Risk of Progression to Multiple Myeloma Can Change Over Time
A risk signature is not constant in a given patient over time—it is subject to change depending on a variety of factors. -
Previously Hidden FDA Data Reveal a Multitude of Adverse Events Linked to Breast Implants
Why were adverse events reported through an alternative reporting channel as opposed to a more transparent means? -
Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies. -
A Tool to Select Candidates for Allogeneic Hematopoietic Cell Transplant in CLL
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
HEMATOLOGIC CANCER NEWS
Incidence of Leukemias But Not All Cancers Increasing as US Baby Boomers Reach 65
Androgen Therapy in Lower-Risk Myelodysplastic Syndrome Can Result in Hematologic Improvement
Patient Preferences Explored in Multiple Myeloma Treatment
Tumor-Initiating Cell Marker Identified in Myeloma
Genetic Overlap Between Autoimmune Disease and NHL Not Supported by Genome-Wide Association Study
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
